FDA Approves YUVEZZI, First Dual-Agent Eye Drop for Presbyopia Treatment
核心洞察
The FDA has approved YUVEZZI (搜索) (carbachol and brimonidine tartrate ophthalmic solution) as the first and only dual-agent eye drop for treating presbyopia (搜索) in adults.
Clinical trials involving over 800 patients demonstrated statistically significant three-line or greater improvement in near vision over 8 hours with once-daily dosing.
The treatment showed favorable safety profile with no treatment-related serious adverse events observed across more than 72,000 treatment days in the longest presbyopia (搜索) safety study to date.
The U.S. Food and Drug Administration has approved YUVEZZI (搜索) (carbachol and brimonidine tartrate ophthalmic solution) 2.75%/0.1%, marking the first dual-agent eye drop specifically designed for presbyopia (搜索) treatment in adults. Developed by Tenpoint Therapeutics (搜索) Ltd., the therapy addresses a condition affecting approximately 128 million people in the United States and two billion globally.
Clinical Trial Results Support Approval
The FDA approval is based on positive data from two pivotal Phase 3 studies enrolling more than 800 patients. The BRIO I study demonstrated superior benefit of the combination therapy over individual active components, meeting FDA requirements for fixed-dose combination approval. In the vehicle-controlled BRIO II study, YUVEZZI (搜索) achieved all primary near vision improvement endpoints with statistically significant three-line or greater improvement in binocular uncorrected near visual acuity (BUNVA) over 8 hours, without loss of one line or more in binocular uncorrected distance visual acuity (BUDVA).
The treatment demonstrated sustained efficacy, achieving miosis from 30 minutes up to 10 hours with once-daily administration. BRIO II also served as the longest safety study conducted in presbyopia (搜索) to date, monitoring patients for 12 months across more than 72,000 treatment days.
Safety Profile and Tolerability
YUVEZZI (搜索) showed a favorable safety profile with no treatment-related serious adverse events observed during clinical trials. The most common side effects reported were headache, impaired vision, and temporary eye pain or eye irritation. Notably, eye redness was not commonly reported, with ocular hyperemia rates of 2.8% for YUVEZZI compared to 10.7% for carbachol alone in the BRIO II study.
Mechanism of Action
The dual-agent formulation combines carbachol, a cholinergic agent that produces constriction of the iris sphincter (搜索) and ciliary body (搜索), with brimonidine tartrate, an alpha-adrenergic agonist that blocks contraction of the iris dilator muscle (搜索). This combination creates pupillary constriction and a pinhole effect that improves near visual acuity and depth of focus while enhancing selectivity for the pupil and increasing carbachol bioavailability in the aqueous humor.
Clinical Impact and Market Availability
"The FDA approval of YUVEZZI (搜索) represents a significant milestone for the millions of people in the U.S. living with presbyopia (搜索) and its daily frustrations and challenges," said Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics (搜索). "As the first FDA-approved dual-agent eye drop for presbyopia, YUVEZZI leverages the mechanisms of carbachol and brimonidine tartrate to deliver sharp near vision with favorable tolerability."
Dr. John Hovanesian of Harvard Eye Associates noted that "current solutions like glasses, contacts or surgery have fallen short in meeting the real-world needs of people who struggle with close-up tasks. YUVEZZI (搜索) introduces a novel approach by combining carbachol and brimonidine tartrate in a single daily eye drop that sharpens near vision and maintains tolerability throughout the day."
YUVEZZI (搜索) is expected to be broadly commercially available in the United States in Q2 2026, providing a new non-invasive treatment option for presbyopia (搜索), which typically begins around age 45 and represents a natural, inevitable part of aging that significantly affects quality of life.